Global Perioral Dermatitis Treatment Market, By Treatment (Immunosuppressive Agents, Topical Ivermectin, Antibiotics, Others), Diagnosis (Physical Examination, Skin Biopsy, Others), Dosage (Injection, Tablets, Ointments, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Perioral Dermatitis Treatment Market Analysis and Size
The number of cases of perioral dermatitis has increased dramatically in the upcoming years. Along with this, the incidence rate of lifestyle or other chronic diseases is high, including the increasing use of topical and inhaled steroids. These are the major factors increasing the risk of perioral dermatitis. High use of topical steroids is the most likely cause of perioral dermatitis.
Data Bridge Market Research analyses a growth rate in the perioral dermatitis treatment market in the forecast period 2023-2030. The expected CAGR of perioral dermatitis treatment market is tend to be around 6.7% in the mentioned forecast period. The market value is USD 66.15 million in 2022, and it would grow up to USD 111.14 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Perioral Dermatitis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Immunosuppressive Agents, Topical Ivermectin, Antibiotics, Others), Diagnosis (Physical Examination, Skin Biopsy, Others), Dosage (Injection, Tablets, Ointments, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), AstraZeneca (U.K.), Merck & Co., Inc. (U.S.), Sumitomo Corporation (Japan), LEO Pharma A/S (Denmark), Cipla Inc. (U.S.), Lilly (U.S.), Bayer AG (Germany), Abbott (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.( Israel), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Perioral dermatitis is a type of rash which affects the area around the mouth and causes inflammation. The rash will extend up the nose or even into the eyes. The common symptom of this condition is a scaly or red bumpy rash. Lesions on darker skin can be hyperpigmented or brown. Antibiotics can be advantageous for a few weeks, whether oral or topically. Azelaic acid is a prescription-only topical medication. When treatment is disturbed, the problem may reoccur, but the same therapy can be restarted as needed.
Perioral Dermatitis Treatment Market Dynamics
Drivers
- Growing Adoption of Corticosteroids
The increase in prevalence rate of chronic diseases will lead to the growing usage of corticosteroid medications that will further enhance the enhancemnet of the growth rate. Topical or inhaled corticosteroids can activate the perioral dermatitis. Thus, this growing use is boosting the market growth.
- Rising Healthcare Expenditure
A primary factor boosting the growth rate of perioral dermatitis treatment market is the rising healthcare expenditure which helps in improving its improved infrastructure. Furthermore, several government organizations aims to expand the healthcare infrastructure by increasing funding and this will consequently influence the market dynamics. Therefore, it boost the market growth.
Opportunities
- Increasing Cases of Rosacea
Incidence rates for ocular involvement in rosacea patients vary from less than 10 % to more than 50 %. Cutaneous rosacea shows a strong female predominance, with the exception of phymatous rosacea, and is generally diagnosed post 30 years of age. There is a scarcity of epidemiological data on rosacea, with reported incidence rates varying from as little as 0.09% to as much as 22.00%. Thus,this creates opportunity for more treatment types.
Restraints/Challenges
- Complications Associated with Treatment Methods
There are several medications that cause burning, itching, skin dryness, or hypopigmentation. Using the topical drug Metronidazole may surge the risk of cancer and antibiotic resistance,. Thus, all these restrain the market growth.
- Increased Cost of Treatment
The high cost that is required for numerous treatment methods hinders market growth. Numerous market players make some huge investments in manufacturing advanced treatment techniques to increase the recovery process, and in return, the cost is increased.
This perioral dermatitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the perioral dermatitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, Glenmark Pharma had received the approval of U.S. Food and Drug Administration for generic antibiotic cream called Clindamycin Phosphate Foam. It is primarily used for the treatment of bacterial infection. Clindamycin Phosphate Foam (1%) is Mylan Pharmaceuticals Inc generic version of Evoclin Foam.
Global Perioral Dermatitis Treatment Market Scope
The perioral dermatitis treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Immunosuppressive Agents
- Topical Ivermectin
- Antibiotics
- Others
Diagnosis
- Physical Examination
- Skin Biopsy
- Others
Dosage
- Physical Examination
- Skin Biopsy
- Others
Route of Administration
- Oral
- Parenteral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Perioral Dermatitis Treatment Regional Analysis/Insights
The perioral dermatitis treatment market is analyzed and market size insights and trends are provided by treatment, diagnosis, dosage, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the perioral dermatitis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the presence of major key players and well-developed healthcare infrastructure in this region.
Asia-Pacific is considered to grow over the coming years because of the growing patient pool, increasing investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Perioral Dermatitis Treatment Share Analysis
The perioral dermatitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to perioral dermatitis treatment market
Key players operating in the perioral dermatitis treatment market include:
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Merck & Co., Inc. (U.S.)
- Sumitomo Corporation (Japan)
- LEO Pharma A/S (Denmark)
- Cipla Inc. (U.S.)
- Lilly (U.S.)
- Bayer AG (Germany)
- Abbott (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd.( Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Bausch Health Companies Inc. (Canada)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
SKU-